Education
About Us
Working with TipRanks
Follow Us
SCYNEXIS (SCYX)
NASDAQ:SCYX
SCYX Stock Chart & Stats
$0.69
-$0.06(-4.73%)
At close: 4:00 PM EST
$0.69
-$0.06(-4.73%)
Day’s Range― - ―
52-Week Range$0.66 - $1.55
Previous CloseN/A
Volume100.07K
Average Volume (3M)612.75K
Market Cap
$28.80M
Enterprise Value-$8.96M
Total Cash (Recent Filing)$44.78M
Total Debt (Recent Filing)$2.39M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Nov 05, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding41,924,942
10 Day Avg. Volume689,890
30 Day Avg. Volume612,753
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.31
Enterprise Value/Revenue-2.75
Enterprise Value/Gross Profit-4.73
Enterprise Value/Ebitda0.31
Forecast
1Y Price Target
$3.50Price Target Upside407.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Financial PositionThe resolution with GSK strengthens the financial position of Scynexis by securing a $22M payment and extending its cash runway to over 2 years.
Market DemandThe global rise in fungal infections creates a growing need for next-generation antifungals like SCY-247.
Product DevelopmentThe focus remains on advancing SCY-247, a next-generation antifungal, following positive Phase 1 data in healthy subjects.
Bears Say
SCYNEXIS News
SCYX FAQ
What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest stock price was $0.66 and its highest was $1.55 in the past 12 months.
What is SCYNEXIS’s market cap?
SCYNEXIS’s market cap is $28.80M.
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s upcoming earnings report date is Nov 05, 2025 which is in 5 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on Aug 13, 2025. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.19 by $0.05.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Undervalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is -0.2.
How many shares outstanding does SCYNEXIS have?
SCYNEXIS has 41,924,942 shares outstanding.
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.19. Following the earnings report the stock price went down -4.762%.
Which hedge fund is a major shareholder of SCYNEXIS?
Currently, no hedge funds are holding shares in SCYX
Company Description
SCYNEXIS
SCYNEXIS, Inc. is a biotechnology company focused on the development and commercialization of innovative therapies for difficult-to-treat infections. The company primarily operates in the biotechnology and pharmaceuticals sector, with a core focus on antifungal treatments. SCYNEXIS is known for its lead product, BREXAFEMME (ibrexafungerp), an oral antifungal drug designed to address fungal infections, particularly those caused by Candida species.
SCYX Stock 12 Month Forecast
Average Price Target
$3.50
▲(407.25% Upside)
Technical Analysis
Rockwell Med
―
TherapeuticsMD
―
Aytu BioScience
―
Cumberland Pharmaceuticals
―
IM Cannabis Corp
―
Ownership Overview
4.64% Insiders
19.74% Mutual Funds
<0.01% Other Institutional Investors
71.67% Public Companies and
Individual Investors